Clinical Trial

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Study acronym: TRANSCEND
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-22; most recent amendment 2025-04-23.
Status change: Not Yet Recruiting → Recruiting 2025-04-23
Trial Details
NCT Number NCT06518720
Lead Sponsor Centre for Addiction and Mental Health
Conditions Treatment Resistant Depression, Chronic Pain
Enrollment 16 participants
Start Date 2025-04-01
Primary Completion 2027-03 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30